-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The results, published recently in the British online journal Scientific Reports, show that a team of researchers, including Yamano Huimei of Osaka City University in Japan, found, through metabolic group analysis, that there are metabolic substances with characteristics in the plasma composition of patients with chronic fatigue syndrome (CFS) for unknown causes.
CFS is a disease that lasts for more than half a year and has a strong sense of burnout and is difficult to adapt to normal social life.
currently in the usual diagnosis and medical examination, it is not possible to detect physical abnormalities with obvious characteristics, nor can it establish a cure.
It is speculated that the cause of the disease may be viral and bacterial infections, excessive stress and other compound factors caused by the nervous system, immune system and endocrine metabolic system disorders, resulting in brain and nervous system dysfunction, but scientists still do not understand its detailed structure.
are the metabolic substances in PATIENTs with CFS different from between normal people? After a detailed analysis of the metabolic substance, the researchers found that there were problems with the metabolic dynamics of the cellular energy production system and the urea circulatory system in CFS patients, and that the proportion of acetone, isocric acid, birdine and guarine in the metabolic substance was higher than that of healthy people.
concentrations of metabolites in the plasma may reflect fatigue.
team believes that this indicator can be used as an effective biological marker for objective diagnosis of CFS.
given that changes in metabolites can reflect the state of the disease, targeted treatments can be established by detecting which parts of the patient's energy production metabolic system and urea circulatory system are low-functioning and combined with the patient's condition.
team will further explore whether CFS patients and healthy people are suitable for all groups of people of different races based on the proportion of metabolites.
they will also analyze people with chronic fatigue who have not yet developed the disease to learn more about fatigue disorders and, on this basis, determine the concentration criteria for metabolites as biomarkers.
.